PUBLISHER: Azoth Analytics | PRODUCT CODE: 1446325
PUBLISHER: Azoth Analytics | PRODUCT CODE: 1446325
Global IgG Mediated Autoimmune Diseases Biologic Drugs Market (2024 Edition): Analysis By Antibody Source (Humanized, Fully Human, Chimeric, Other Sources), By Indication, By Region, By Country: Market Insights and Forecast (2019-2029)
Executive Summary
Azoth Analytics has released a research report titled "Global IgG Mediated Autoimmune Diseases Biologic Drugs Market (2024 Edition)" which provides a complete analysis of the Global IgG Mediated Autoimmune Diseases Biologic Drugs industry in terms of market segmentation By Antibody Source (Humanized, Fully Human, Chimeric, Other Antibody Sources), By Indication (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis and Other Indications) for the historical period of 2019-2022, the estimates of 2023 and the forecast period of 2024-2029.
The report analyses the IgG Mediated Autoimmune Diseases Biologic Drugs Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, South India). The Global IgG Mediated Autoimmune Diseases Biologic Drugs market showcased growth at a CAGR of 7.25% during 2019-2022. The market was valued at USD 123.99 Billion in 2022 which is expected to reach USD 197.78 Billion in 2029. The increasing incidence and prevalence of IgG mediated autoimmune diseases such as rheumatoid arthritis, lupus, and psoriasis are major drivers for the growth of biologic drugs.
Factors such as genetic predisposition, environmental triggers, and lifestyle changes contribute to the rising burden of autoimmune diseases globally. Additionally, The aging population worldwide is more susceptible to autoimmune diseases, driving the demand for biologic drugs. Elderly individuals often experience multiple comorbidities and may require more targeted and effective treatments, contributing to the expansion of the biologic drugs market.
Biologic drugs for IgG mediated autoimmune diseases represent a significant advancement in medical treatment, as they are meticulously engineered to selectively target key components of the immune system implicated in the pathogenesis of these diseases. This precision targeting distinguishes them from conventional treatments, which often have broader mechanisms of action and can lead to more generalized effects.
For instance, these biologic drugs may directly inhibit certain pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-a) or interleukins (ILs), which play crucial roles in promoting inflammation and tissue damage in autoimmune conditions like rheumatoid arthritis or inflammatory bowel disease. By specifically targeting these cytokines, biologic therapies can disrupt the inflammatory cascade at its source, thereby alleviating symptoms and preventing disease progression more effectively than traditional therapies.
The global market for IgG mediated autoimmune diseases biologic drugs is highly competitive, with numerous pharmaceutical companies and biotechnology firms competing for market share.
Scope of the Report
- The report analyses the IgG Mediated Autoimmune Diseases Biologic Drugs Market by Value (USD Billion).
- The report presents the analysis of IgG Mediated Autoimmune Diseases Biologic Drugs Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
- The report analyses the IgG Mediated Autoimmune Diseases Biologic Drugs Market By Antibody Source (Humanized, Fully Human, Chimeric, Other Antibody Sources)
- The report analyses the IgG Mediated Autoimmune Diseases Biologic Drugs Market By Indication (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis and Other Indications).
- The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Antibody Sources, by mode of operation & by end users.
- Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
- The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Johnson & Johnson, Pfizer, Novartis AG, Roche Holding AG, Eli Lilly and Company, Abbvie Inc., Sanofi, GSK plc., and UCB S.A
Azoth Analytics has released a research report titled "Global Simulation and Analysis Market (2024 Edition)" which provides a complete analysis of the Global Simulation and Analysis Market industry in terms of market segmentation By Component (Software, Service) Deployment (On-premise, Cloud) and End-use (Automotive, Aerospace & Defense, Industrial Manufacturing, Healthcare, Others). The report analyzes the Global Simulation and Analysis Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
The report analyses the Simulation and Analysis Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Brazil, Germany, United Kingdom, France, China, Japan, South Korea, India). The research study also assesses growth indicators, restraints, sales growth and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market's evolution.
During the forecast period, 2024-2029, the Global Simulation and Analysis Market is expected to expand at a CAGR of 8.6%. The global Simulation and Analysis market is expected to grow at an extraordinary rate driven by the significant adoption of simulation tools from key players. The Global Simulation and Analysis market is expected to increase from USD 10.26 billion in 2024 to USD 15.50 billion in 2029, according to Azoth Analytics' estimates. The significance of simulation tools has increased with the advent of the Fourth Industrial Revolution, which is marked by smart manufacturing and networking. With significant market value, the global simulation and analysis market is a dynamic, growing business. It covers a wide range of industries, such as aerospace, automotive, manufacturing, and healthcare. The growing utilization of simulation software in various sectors for process optimization, product development, and operational efficiency is the primary factor driving the market value.
The increasing demand for virtual testing and training solutions, technical improvements, and the integration of simulation across many industries are driving considerable growth in the global simulation and analysis market. Simulation and analysis solutions are being used more and more in a variety of industries, such as aerospace, automotive, healthcare, manufacturing, and defence, for testing, product development, training, and operational optimization.
Growing Advancements in Simulation Software
The rapid development of technology has led to the emergence of increasingly complex and functional simulators that provide improved performance and capabilities. These developments allow companies in a range of industries to run more detailed and lifelike simulations, more accurately simulating complicated real-world situations. The development of simulation software has increased the precision of virtual models and broadened the industries and applications in which they can be used successfully.
Furthermore, as simulation software becomes more sophisticated, manufacturing, product development, and other crucial activities become more productive and efficient. Predictive modelling, optimization, and scenario analysis are made possible by the powerful algorithms, artificial intelligence, and machine learning included in modern simulation programs. The development of simulation software is a strong option for enterprises looking to improve decision-making, reduce expenses, and streamline processes. As more sectors come to understand the importance of these advanced methods in accomplishing their goals, the Simulation and Analysis Market is expected to grow as a result of these tools, which enable organizations to make better decisions, generate innovation, and obtain deeper insights.
Complexity and Integration Issues
The complexity and concerns with integration related to simulation and analysis tools pose significant barriers to the expansion of the worldwide market. The complex nature of these innovative tools, which frequently call for specific knowledge for efficient implementation and use, is one of the main challenges. It can be difficult to integrate simulation software into current workflows and systems, which might cause problems with older systems. Enterprises may encounter challenges in ensuring seamless interaction among diverse simulation tools and systems, hindering the general effectiveness and convenience of these technologies. User-friendly interfaces and seamless integration are becoming essential as industries want to exploit simulation's advantages for better decision-making and efficiency. For simulation and analytic solutions to be widely adopted and for companies to fully benefit from the insights and optimizations these tools can provide across a variety of sectors, these complexity and integration issues must be resolved.
Scope of the Report
- The report analyses the Global Simulation and Analysis Market by Value (USD Billion).
- The report presents the analysis of the Global Simulation and Analysis Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
- The report analyses the Global Simulation and Analysis Market by Component (Software, Service).
- The report analyses the Simulation and Analysis Market by Deployment (On-premise, Cloud).
- The report analyses the Simulation and Analysis Market by End-use (Automotive, Aerospace & Defense, Industrial Manufacturing, Healthcare, Others).
- The report analyses the Simulation and Analysis Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa).
- The report analyses the Simulation and Analysis Market by Country (United States, Canada, Brazil, Germany, United Kingdom, France, China, Japan, South Korea, India).
- The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis.
- Also, the major opportunities, trends, drivers and challenges of the industry have been analyzed in the report.
- The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Altair Engineering Inc., Ansys, Inc., Autodesk, Inc., Dassault Systemes, Certara, Inc., Hexagon AB, Keysight Technologies, Simulations Plus, Inc., Gamma Technologies and Siemens Digital Industries Software.
Table of Contents
Table of Content
1. Market Background
- 1.1 Scope and Product Outlook
- 1.2 Executive Summary
- 1.3 Research Methodology
2. Analyst Recommendations
- 2.1 Shift towards targeted therapies and personalized medicine
- 2.2 Adoption of biosimilars and biobetters
3. Global IgG-mediated Autoimmune Disease Biologic Drugs Market: Historic and Forecast
- 3.1 Impact Analysis of Macro Economic Factors on Global IgG-mediated Autoimmune Disease Biologic Drugs Market
- 3.2 Biologics in Pipeline for Rheumatoid Arthritis
- 3.3 Biologics in Pipeline for Multiple Sclerosis
- 3.4 Biologics in Pipeline for Systemic Lupus Erythematosus
- 3.5 Ten top-selling antibodies globally, 2019
- 3.6 Global IgG-mediated Autoimmune Disease Biologic Drugs Market: Dashboard
- 3.7 Global IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
- 3.8 Global IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Value Assessment
- 3.9 Assessment Degree of Impact of COVID-19 on Global IgG-mediated Autoimmune Disease Biologic Drugs Market
- 3.10 Global IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Antibody Source
- 3.10.1 Global IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source Overview
- 3.10.2 Global IgG-mediated Autoimmune Disease Biologic Drugs Market Attractiveness Index, By Antibody Source
- 3.10.3 Global IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Fully Human, By Value, 2019H-2029F (USD Billion & CAGR)
- 3.10.4 Global IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Humanized, By Value, 2019H-2029F (USD Billion & CAGR)
- 3.10.5 Global IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Chimeric, By Value, 2019H-2029F (USD Billion & CAGR)
- 3.10.6 Global IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Other Antibody Sources, By Value, 2019H-2029F (USD Billion & CAGR)
- 3.11 Global IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Indication
- 3.11.1 Global IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication Overview
- 3.11.2 Global IgG-mediated Autoimmune Disease Biologic Drugs Market Attractiveness Index, By Indication
- 3.11.2 Global IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Rheumatoid Arthritis, By Value, 2019H-2029F (USD Billion & CAGR)
- 3.11.3 Global IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Systemic Lupus Erythematosus, By Value, 2019H-2029F (USD Billion & CAGR)
- 3.11.4 Global IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Multiple Sclerosis, By Value, 2019H-2029F (USD Billion & CAGR)
- 3.11.5 Global IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)
4 IgG-mediated Autoimmune Disease Biologic Drugs Market, Region Analysis
- 4.1 Regional Coverage of the Study
- 4.2 Regional Snapshot
5 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market: Historic and Forecast
- 5.1 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market: Snapshot
- 5.2 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
- 5.3 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market: Key Factors
- 5.4 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market: Segment Analysis
- 5.5 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Antibody Source
- 5.5.1 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source Overview
- 5.5.2 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Fully Human, By Value, 2019H-2029F (USD Billion & CAGR)
- 5.5.3 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Humanized, By Value, 2019H-2029F (USD Billion & CAGR)
- 5.5.4 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Chimeric, By Value, 2019H-2029F (USD Billion & CAGR)
- 5.5.5 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Other Antibody Sources, By Value, 2019H-2029F (USD Billion & CAGR)
- 5.6 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Indication
- 5.6.1 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication Overview
- 5.6.2 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Rheumatoid Arthritis, By Value, 2019H-2029F (USD Billion & CAGR)
- 5.6.3 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Systemic Lupus Erythematosus, By Value, 2019H-2029F (USD Billion & CAGR)
- 5.6.4 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Multiple Sclerosis, By Value, 2019H-2029F (USD Billion & CAGR)
- 5.6.5 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)
- 5.7 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Country
- 5.7.1 Americas IgG-mediated Autoimmune Disease Biologic Drugs Market, by Country Overview
- 5.7.2 United States IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
- 5.7.2.1 United States IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
- 5.7.2.2 United States IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
- 5.7.3 Canada IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
- 5.7.3.1 Canada IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
- 5.7.3.2 Canada IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
- 5.7.4 Rest of Americas IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
- 5.7.5.1 Rest of Americas IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
- 5.7.5.2 Rest of Americas IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
6. Europe IgG-mediated Autoimmune Disease Biologic Drugs Market: Historic and Forecast
- 6.1 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market: Snapshot
- 6.2 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
- 6.3 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market: Key Factors
- 6.4 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market: Segment Analysis
- 6.5 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Antibody Source
- 6.5.1 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source Overview
- 6.5.2 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Fully Human, By Value, 2019H-2029F (USD Billion & CAGR)
- 6.5.3 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Humanized, By Value, 2019H-2029F (USD Billion & CAGR)
- 6.5.4 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Chimeric, By Value, 2019H-2029F (USD Billion & CAGR)
- 6.5.5 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Other Antibody Sources, By Value, 2019H-2029F (USD Billion & CAGR)
- 6.6 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Indication
- 6.6.1 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication Overview
- 6.6.2 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Rheumatoid Arthritis, By Value, 2019H-2029F (USD Billion & CAGR)
- 6.6.3 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Systemic Lupus Erythematosus, By Value, 2019H-2029F (USD Billion & CAGR)
- 6.6.4 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Multiple Sclerosis, By Value, 2019H-2029F (USD Billion & CAGR)
- 6.6.5 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)
- 6.7 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Country
- 6.7.1 Europe IgG-mediated Autoimmune Disease Biologic Drugs Market, by Country Overview
- 6.7.2 United Kingdom IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
- 6.7.2.1 United Kingdom IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
- 6.7.2.2 United Kingdom IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
- 6.7.3 Germany IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
- 6.7.3.1 Germany IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
- 6.7.3.2 Germany IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
- 6.7.4 France IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
- 6.7.4.1 France IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
- 6.7.4.2 France IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
- 6.7.5 Italy IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
- 6.7.5.1 Italy IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
- 6.7.5.2 Italy IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
- 6.7.6 Spain IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
- 6.7.6.1 Spain IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
- 6.7.6.2 Spain IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
- 6.7.6 Rest of Europe IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
- 6.7.6.1 Rest of Europe IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
- 6.7.6.2 Rest of Europe IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
7. Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market: Historic and Forecast
- 7.1 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market: Snapshot
- 7.2 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
- 7.3 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market: Key Factors
- 7.4 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market: Segment Analysis
- 7.5 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Antibody Source
- 7.5.1 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source Overview
- 7.5.2 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Fully Human, By Value, 2019H-2029F (USD Billion & CAGR)
- 7.5.3 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Humanized, By Value, 2019H-2029F (USD Billion & CAGR)
- 7.5.4 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Chimeric, By Value, 2019H-2029F (USD Billion & CAGR)
- 7.5.5 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Other Antibody Sources, By Value, 2019H-2029F (USD Billion & CAGR)
- 7.6 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Indication
- 7.6.1 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication Overview
- 7.6.2 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Rheumatoid Arthritis, By Value, 2019H-2029F (USD Billion & CAGR)
- 7.6.3 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Systemic Lupus Erythematosus, By Value, 2019H-2029F (USD Billion & CAGR)
- 7.6.4 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Multiple Sclerosis, By Value, 2019H-2029F (USD Billion & CAGR)
- 7.6.5 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)
- 7.7 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Country
- 7.7.1 Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market, by Country Overview
- 7.7.2 China IgG-mediated Autoimmune Disease Biologic Drugs Market : Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
- 7.7.2.1 China IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
- 7.7.2.2 China IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
- 7.7.3 Japan IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
- 7.7.3.1 Japan IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
- 7.7.3.2 Japan IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
- 7.7.4 India IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
- 7.7.4.1 India IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
- 7.7.4.2 India IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
- 7.7.5 Rest of Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
- 7.7.5.1 Rest of Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source
- 7.7.5.2 Rest of Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication
8. Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market: Historic and Forecast
- 8.1 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market: Snapshot
- 8.2 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
- 8.3 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market: Key Factors
- 8.4 Middle East and Africa IgG-mediated Autoimmune Disease Biologic Drugs Market: Segment Analysis
- 8.5 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Antibody Source
- 8.5.1 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source Overview
- 8.5.2 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Fully Human, By Value, 2019H-2029F (USD Billion & CAGR)
- 8.5.3 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Humanized, By Value, 2019H-2029F (USD Billion & CAGR)
- 8.5.3 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Chimeric, By Value, 2019H-2029F (USD Billion & CAGR)
- 8.5.5 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Other Antibody Sources By Value, 2019H-2029F (USD Billion & CAGR)
- 8.6 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market Segmentation : By Indication
- 8.6.1 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication Overview
- 8.6.2 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Rheumatoid Arthritis, By Value, 2019H-2029F (USD Billion & CAGR)
- 8.6.3 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Systemic Lupus Erythematosus, By Value, 2019H-2029F (USD Billion & CAGR)
- 8.6.4 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Multiple Sclerosis, By Value, 2019H-2029F (USD Billion & CAGR)
- 8.6.5 Middle East & Africa IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)
9. Market Dynamics
- 9.1 Impact assessment of Market Dynamics on IgG-mediated Autoimmune Disease Biologic Drugs Market
- 9.2 Drivers
- 9.3 Restraints
- 9.4 Trends
10. Industry Ecosystem Analysis
- 10.1 Porter Analysis
11. Competitive Positioning
- 11.1 Companies' Product Positioning
- 11.2 Market Position Matrix
- 11.3 Market Share Analysis of IgG-mediated Autoimmune Disease Biologic Drugs Market
- 11.4 Company Profiles
- 11.4.1 Johnson & Johnson
- 11.4.2 Pfizer
- 11.4.3 Novartis AG
- 11.4.4 Roche Holding AG
- 11.4.5 Eli Lilly and Company
- 11.4.6 Abbvie Inc.
- 11.4.7 Sanofi
- 11.4.8 GSK plc.
- 11.4.9 UCB S.A
12. About Us & Disclaimer
List of Figures
List of Figures
- Figure 1: Global IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Value, 2019-2022 (USD Billion)
- Figure 2: Global IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Value, 2023-2029 (USD Billion)
- Figure 3: Global IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Indication, 2022 (%)
- Figure 4: Global IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Fully Human, By Value, 2019H-2029F (USD Billions & CAGR)
- Figure 5: Global IgG-mediated Autoimmune Disease Biologic Drugs Market Absolute Opportunity, By Fully Human, 2019-2029 (USD Billion)
- Figure 6: Global IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Humanized, By Value, 2019H-2029F (USD Billions & CAGR)
- Figure 7: Global IgG-mediated Autoimmune Disease Biologic Drugs Market Absolute Opportunity, By Humanized, 2019-2029 (USD Billion)
- Figure 8: Global IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Chimeric, By Value, 2019H-2029F (USD Billions & CAGR)
- Figure 9: Global IgG-mediated Autoimmune Disease Biologic Drugs Market Absolute Opportunity, By Chimeric, 2019-2029 (USD Billion)
- Figure 10: Global IgG-mediated Autoimmune Disease Biologic Drugs Market Absolute Opportunity, By Chimeric, 2019-2029 (USD Billion)
- Figure 11: Global IgG-mediated Autoimmune Disease Biologic Drugs Market Absolute Opportunity, By Other Antibody Sources, 2019-2029 (USD Billion)
- Figure 12: Global IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Rheumatoid Arthritis, By Value, 2019H-2029F (USD Billions & CAGR)
- Figure 13: Global IgG-mediated Autoimmune Disease Biologic Drugs Market Absolute Opportunity, By Rheumatoid Arthritis, 2019-2029 (USD Billion)
- Figure 14: Global IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Systemic Lupus Erythematosus, By Value, 2019H-2029F (USD Billions & CAGR)
- Figure 15: Global IgG-mediated Autoimmune Disease Biologic Drugs Market Absolute Opportunity, By Systemic Lupus Erythematosus, 2019-2029 (USD Billion)
- Figure 16: Global IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Multiple Sclerosis, By Value, 2019H-2029F (USD Billions & CAGR)
- Figure 17: Global IgG-mediated Autoimmune Disease Biologic Drugs Market Absolute Opportunity, By Multiple Sclerosis, 2019-2029 (USD Billion)
- Figure 18: Global IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Other Indications, By Value, 2019H-2029F (USD Billions & CAGR)
- Figure 19: Global IgG-mediated Autoimmune Disease Biologic Drugs Market Absolute Opportunity, By Other Indications, 2019-2029 (USD Billion)
- Figure 20: Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Value, 2019H-2029F (USD Billion)
- Figure 21: Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Indication, 2022 (%)
- Figure 22: Americas IgG-mediated Autoimmune Disease Biologic Drugs Market, By Fully Human, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 23: Americas IgG-mediated Autoimmune Disease Biologic Drugs Market, By Humanized, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 24: Americas IgG-mediated Autoimmune Disease Biologic Drugs Market, By Chimeric, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 25: Americas IgG-mediated Autoimmune Disease Biologic Drugs Market, By Other Antibody Sources, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 26: Americas IgG-mediated Autoimmune Disease Biologic Drugs Market, By Rheumatoid Arthritis, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 27: Americas IgG-mediated Autoimmune Disease Biologic Drugs Market, By Systemic Lupus Erythematosus, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 28: Americas IgG-mediated Autoimmune Disease Biologic Drugs Market, By Multiple Sclerosis, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 29: Americas IgG-mediated Autoimmune Disease Biologic Drugs Market, By Other Indications, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 30: United States IgG-mediated Autoimmune Disease Biologic Drugs Market, By Value, 2019-2029 (USD Billions & CAGR)
- Figure 31: United States IgG-mediated Autoimmune Disease Biologic Drugs Market Value, By Indication, 2022 (USD Billion)
- Figure 32: United States IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Antibody Source, By Value, 2022 (%)
- Figure 33: United States IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Indication, By Value, 2022 (%)
- Figure 34: Canada IgG-mediated Autoimmune Disease Biologic Drugs Market, By Value, 2019-2029 (USD Billions & CAGR)
- Figure 35: Canada IgG-mediated Autoimmune Disease Biologic Drugs Market Value, By Indication, 2022 (USD Billion)
- Figure 36: Canada IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Antibody Source, By Value, 2022 (%)
- Figure 37: Canada IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Indication, By Value, 2022 (%)
- Figure 38: Rest of Americas IgG-mediated Autoimmune Disease Biologic Drugs Market, By Value, 2019-2029 (USD Billions & CAGR)
- Figure 39: Rest of Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Value, By Indication, 2022 (USD Billion)
- Figure 40: Rest of Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Antibody Source, By Value, 2022 (%)
- Figure 41: Rest of Americas IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Indication, By Value, 2022 (%)
- Figure 42: Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Value, 2019H-2029F (USD Billion)
- Figure 43: Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Indication, 2022 (%)
- Figure 44: Europe IgG-mediated Autoimmune Disease Biologic Drugs Market, By Fully Human, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 45: Europe IgG-mediated Autoimmune Disease Biologic Drugs Market, By Humanized, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 46: Europe IgG-mediated Autoimmune Disease Biologic Drugs Market, By Chimeric, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 47: Europe IgG-mediated Autoimmune Disease Biologic Drugs Market, By Other Antibody Sources, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 48: Europe IgG-mediated Autoimmune Disease Biologic Drugs Market, By Rheumatoid Arthritis, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 49: Europe IgG-mediated Autoimmune Disease Biologic Drugs Market, By Systemic Lupus Erythematosus, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 50: Europe IgG-mediated Autoimmune Disease Biologic Drugs Market, By Multiple Sclerosis, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 51: Europe IgG-mediated Autoimmune Disease Biologic Drugs Market, By Other Indications, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 52: United Kingdom IgG-mediated Autoimmune Disease Biologic Drugs Market, By Value, 2019-2029 (USD Billions & CAGR)
- Figure 53: United Kingdom IgG-mediated Autoimmune Disease Biologic Drugs Market Value, By Indication, 2022 (USD Billion)
- Figure 54: United Kingdom IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Antibody Source, By Value, 2022 (%)
- Figure 55: United Kingdom IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Indication, By Value, 2022 (%)
- Figure 56: Germany IgG-mediated Autoimmune Disease Biologic Drugs Market, By Value, 2019-2029 (USD Billions & CAGR)
- Figure 57: Germany IgG-mediated Autoimmune Disease Biologic Drugs Market Value, By Indication, 2022 (USD Billion)
- Figure 58: Germany IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Antibody Source, By Value, 2022 (%)
- Figure 59: Germany IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Indication, By Value, 2022 (%)
- Figure 60: France IgG-mediated Autoimmune Disease Biologic Drugs Market, By Value, 2019-2029 (USD Billions & CAGR)
- Figure 61: France IgG-mediated Autoimmune Disease Biologic Drugs Market Value, By Indication, 2022 (USD Billion)
- Figure 62: France IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Antibody Source, By Value, 2022 (%)
- Figure 63: France IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Indication, By Value, 2022 (%)
- Figure 64: Italy IgG-mediated Autoimmune Disease Biologic Drugs Market, By Value, 2019-2029 (USD Billions & CAGR)
- Figure 65: Italy IgG-mediated Autoimmune Disease Biologic Drugs Market Value, By Indication, 2022 (USD Billion)
- Figure 66: Italy IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Antibody Source, By Value, 2022 (%)
- Figure 67: Italy IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Indication, By Value, 2022 (%)
- Figure 68: Spain IgG-mediated Autoimmune Disease Biologic Drugs Market, By Value, 2019-2029 (USD Billions & CAGR)
- Figure 69: Spain IgG-mediated Autoimmune Disease Biologic Drugs Market Value, By Indication, 2022 (USD Billion)
- Figure 70: Spain IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Antibody Source, By Value, 2022 (%)
- Figure 71: Spain IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Indication, By Value, 2022 (%)
- Figure 72: Rest of Europe IgG-mediated Autoimmune Disease Biologic Drugs Market, By Value, 2019-2029 (USD Billions & CAGR)
- Figure 73: Rest of Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Value, By Indication, 2022 (USD Billion)
- Figure 74: Rest of Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Antibody Source, By Value, 2022 (%)
- Figure 75: Rest of Europe IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Indication, By Value, 2022 (%)
- Figure 76: Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Value, 2019H-2029F (USD Billion)
- Figure 77: Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Indication, 2022 (%)
- Figure 78: Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market, By Fully Human, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 79: Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market, By Humanized, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 80: Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market, By Chimeric, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 81: Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market, By Other Antibody Sources, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 82: Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market, By Rheumatoid Arthritis, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 83: Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market, By Systemic Lupus Erythematosus, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 84: Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market, By Multiple Sclerosis, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 85: Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market, By Other Indications, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 86: China IgG-mediated Autoimmune Disease Biologic Drugs Market, By Value, 2019-2029 (USD Billions & CAGR)
- Figure 87: China IgG-mediated Autoimmune Disease Biologic Drugs Market Value, By Indication, 2022 (USD Billion)
- Figure 88: China IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Antibody Source, By Value, 2022 (%)
- Figure 89: China IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Indication, By Value, 2022 (%)
- Figure 90: Japan IgG-mediated Autoimmune Disease Biologic Drugs Market, By Value, 2019-2029 (USD Billions & CAGR)
- Figure 91: Japan IgG-mediated Autoimmune Disease Biologic Drugs Market Value, By Indication, 2022 (USD Billion)
- Figure 92: Japan IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Antibody Source, By Value, 2022 (%)
- Figure 93: Japan IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Indication, By Value, 2022 (%)
- Figure 94: India IgG-mediated Autoimmune Disease Biologic Drugs Market, By Value, 2019-2029 (USD Billions & CAGR)
- Figure 95: India IgG-mediated Autoimmune Disease Biologic Drugs Market Value, By Indication, 2022 (USD Billion)
- Figure 96: India IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Antibody Source, By Value, 2022 (%)
- Figure 97: India IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Indication, By Value, 2022 (%)
- Figure 98: Rest of Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market, By Value, 2019-2029 (USD Billions & CAGR)
- Figure 99: Rest of Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Value, By Indication, 2022 (USD Billion)
- Figure 100: Rest of Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Antibody Source, By Value, 2022 (%)
- Figure 101: Rest of Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Indication, By Value, 2022 (%)
- Figure 102: Middle East and Africa IgG-mediated Autoimmune Disease Biologic Drugs Market Size, By Value, 2019H-2029F (USD Billion)
- Figure 103: Middle East and Africa IgG-mediated Autoimmune Disease Biologic Drugs Market Share, By Indication, 2022 (%)
- Figure 104: Middle East and Africa IgG-mediated Autoimmune Disease Biologic Drugs Market, By Fully Human, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 105: Middle East and Africa IgG-mediated Autoimmune Disease Biologic Drugs Market, By Humanized, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 106: Middle East and Africa IgG-mediated Autoimmune Disease Biologic Drugs Market, By Chimeric, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 107: Middle East and Africa IgG-mediated Autoimmune Disease Biologic Drugs Market, By Other Antibody Sources, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 108: Middle East and Africa IgG-mediated Autoimmune Disease Biologic Drugs Market, By Rheumatoid Arthritis, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 109: Middle East and Africa IgG-mediated Autoimmune Disease Biologic Drugs Market, By Systemic Lupus Erythematosus, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 110: Middle East and Africa IgG-mediated Autoimmune Disease Biologic Drugs Market, By Multiple Sclerosis, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 111: Middle East and Africa IgG-mediated Autoimmune Disease Biologic Drugs Market, By Other Indications, By Value, 2019H-2029F (USD Millions & CAGR)
- Figure 112: Market Share of Prominent Companies of IgG-mediated Autoimmune Disease Biologic Drugs Market, 2022 (%)
- Figure 113: Johnson & Johnson Revenues, 2020-2022 (USD Million)
- Figure 114: Johnson & Johnson Revenues, By Geographic Segments, 2022 (%)
- Figure 115: Johnson & Johnson Revenue , By Business Segments, 2022 (%)
- Figure 116: Pfizer Revenues, 2020-2022 (USD Million)
- Figure 117: Pfizer Revenues, By Business Segments, 2022 (%)
- Figure 118: Pfizer Inc. Revenue , By Geographical Segments, 2022 (%)
- Figure 119: Novartis Revenue, 2020-2022 (USD Million)
- Figure 120: Novartis Revenue, By Business Segments, 2022 (%)
- Figure 121: Novartis Revenue, By Geographical Segments, 2022 (%)
- Figure 122: Roche Revenue, 2020-2022 (USD Million)
- Figure 123: Roche Revenue, By Business Segments, 2022 (%)
- Figure 124: Roche Revenue, By Business Segments, 2022 (%)
- Figure 125: Eli Lilly and Company Revenues, 2020-2022 (USD Million)
- Figure 126: Eli Lilly and Company Revenues, By Geographic Segments, 2022 (%)
- Figure 127: Eli Lilly and Company Revenue , By Therapeutic Area, 2022 (%)
- Figure 128: AbbVie Inc. Revenues, 2020-2022 (USD Million)
- Figure 129: AbbVie Inc. Revenue , Product Category, 2022 (%)
- Figure 130: AbbVie Inc. Revenue , By Geographical Segments, 2022 (%)
- Figure 131: Sanofi Revenues, 2020-2022 (USD Million)
- Figure 132: Sanofi Revenues, By Geographic Segments, 2022 (%)
- Figure 133: Sanofi Revenue , By Business Segments, 2022 (%)
- Figure 134: GSK PLC Revenue, 2020-2022 (USD Million)
- Figure 135: GSK PLC Revenue , By Business Segments, 2022 (%)
- Figure 136: GSK PLC Revenue, By Geography Segment, 2022 (%)
- Figure 137: UCB S.A. Revenue, 2020-2022 (USD Million)
- Figure 138: UCB S.A. Revenue , By Business Segments, 2022 (%)
- Figure 139: UCB S.A. Revenue, By Geography Segment, 2022 (%)
List of Tables
Table A1: Global Impact of Macro Economic Factors, By Region
Table A2: Biologics in Pipeline for Rheumatoid Arthritis
Table A3: Biologics in Pipeline for Multiple Sclerosis
Table A4: Biologics in Pipeline for Systemic Lupus Erythematosus
Table A5: Ten top-selling antibodies globally, 2019
Table A6: United States IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2019-2022 (USD Billion)
Table A7: United States IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2023-2029 (USD Billion)
Table A8: United States IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A9: United States IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A10: Canada IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2019-2022 (USD Billion)
Table A11: Canada IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2023-2029 (USD Billion)
Table A12: Canada IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A13: Canada IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A14: Rest of Americas IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2019-2022 (USD Billion)
Table A15: Rest of Americas IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2023-2029 (USD Billion)
Table A16: Rest of Americas IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A17: Rest of Americas IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A18: United Kingdom IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2019-2022 (USD Billion)
Table A19: United Kingdom IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2023-2029 (USD Billion)
Table A20: United Kingdom IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A21: United Kingdom IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A22: Germany IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2019-2022 (USD Billion)
Table A23: Germany IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2023-2029 (USD Billion)
Table A24: Germany IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A25: Germany IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A26: France IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2019-2022 (USD Billion)
Table A27: France IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2023-2029 (USD Billion)
Table A28: France IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A29: France IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A30: Italy IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2019-2022 (USD Billion)
Table A31: Italy IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2023-2029 (USD Billion)
Table A32: Italy IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A33: Italy IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A34: Spain IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2019-2022 (USD Billion)
Table A35: Spain IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2023-2029 (USD Billion)
Table A36: Spain IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A37: Spain IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A38: Rest of Europe IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2019-2022 (USD Billion)
Table A39: Rest of Europe IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2023-2029 (USD Billion)
Table A40: Rest of Europe IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A41: Rest of Europe IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A42: China IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2019-2022 (USD Billion)
Table A43: China IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2023-2029 (USD Billion)
Table A44: China IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A45: China IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A46: Japan IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2019-2022 (USD Billion)
Table A47: Japan IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2023-2029 (USD Billion)
Table A48: Japan IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A49: Japan IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A50: India IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2019-2022 (USD Billion)
Table A51: India IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2023-2029 (USD Billion)
Table A52: India IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A53: India IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A54: Rest of Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2019-2022 (USD Billion)
Table A55: Rest of Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market, By Antibody Source, By Value, 2023-2029 (USD Billion)
Table A56: Rest of Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2019-2022 (USD Billion)
Table A57: Rest of Asia Pacific IgG-mediated Autoimmune Disease Biologic Drugs Market, By Indication, By Value, 2023-2029 (USD Billion)
Table A58: Johnson & Johnson Key Financials, 2020-2022
Table A59: Pfizer Key Financials, 2020-2022
Table A60: Novartis Key Company Financials, 2020-2022
Table A61: Roche Key Company Financials, 2020-2022
Table A62: Eli Lilly and Company Key Financials, 2020-2022
Table A63: AbbVie Inc. Company Financials, 2020-2022
Table A64: Sanofi Key Financials, 2020-2022
Table A65: GSK PLC Key Company Financials, 2020-2022
Table A66: UCB S.A. Key Company Financials, 2020-2022
